Abstract
BackgroundSecukinumab (SCK) is a human monoclonal antibody (IgG1) directed against IL-17A, approved for the treatment of plaque psoriasis, psoriatic arthritis (PsA) and axial spondyloarthritis (AxSpA). Data from randomized controlled clinical...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
